首页> 美国卫生研究院文献>Micromachines >Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals
【2h】

Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals

机译:放射性药物微流体质量控制测试的最新进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Radiopharmaceuticals labeled with short-lived positron-emitting or gamma-emitting isotopes are injected into patients just prior to performing positron emission tomography (PET) or single photon emission tomography (SPECT) scans, respectively. These imaging modalities are widely used in clinical care, as well as in the development and evaluation of new therapies in clinical research. Prior to injection, these radiopharmaceuticals (tracers) must undergo quality control (QC) testing to ensure product purity, identity, and safety for human use. Quality tests can be broadly categorized as (i) pharmaceutical tests, needed to ensure molecular identity, physiological compatibility and that no microbiological, pyrogenic, chemical, or particulate contamination is present in the final preparation; and (ii) radioactive tests, needed to ensure proper dosing and that there are no radiochemical and radionuclidic impurities that could interfere with the biodistribution or imaging. Performing the required QC tests is cumbersome and time-consuming, and requires an array of expensive analytical chemistry equipment and significant dedicated lab space. Calibrations, day of use tests, and documentation create an additional burden. Furthermore, in contrast to ordinary pharmaceuticals, each batch of short-lived radiopharmaceuticals must be manufactured and tested within a short period of time to avoid significant losses due to radioactive decay. To meet these challenges, several efforts are underway to develop integrated QC testing instruments that automatically perform and document all of the required tests. More recently, microfluidic quality control systems have been gaining increasing attention due to vastly reduced sample and reagent consumption, shorter analysis times, higher detection sensitivity, increased multiplexing, and reduced instrumentation size. In this review, we describe each of the required QC tests and conventional testing methods, followed by a discussion of efforts to directly miniaturize the test or examples in the literature that could be implemented for miniaturized QC testing.
机译:分别在执行正电子发射断层扫描(PET)或单光子发射断层扫描(SPECT)扫描之前,将标记有短寿命正电子发射或伽马发射同位素的放射性药物分别注入患者体内。这些成像方式已广泛用于临床护理,以及在临床研究中开发和评估新疗法。在注射之前,这些放射性药物(示踪剂)必须经过质量控制(QC)测试,以确保产品的纯度,身份和对人类使用的安全性。质量测试可大致分为以下几类:(i)药物测试,以确保分子身份,生理相容性以及最终制剂中不存在微生物,热原,化学或颗粒污染; (ii)放射性测试,需要确保适当的剂量,并且不存在可能干扰生物分布或成像的放射化学和放射性核素杂质。执行所需的QC测试既麻烦又费时,并且需要一系列昂贵的分析化学设备和大量专用实验室空间。校准,使用日测试和文档增加了负担。此外,与普通药物相比,每批短寿命放射性药物必须在短时间内制造和测试,以避免由于放射性衰变而造​​成的重大损失。为了应对这些挑战,正在采取多种措施来开发可自动执行和记录所有必需测试的集成QC测试仪器。最近,由于大大减少了样品和试剂的消耗,缩短了分析时间,提高了检测灵敏度,增加了多路复用并减小了仪器尺寸,微流体质量控制系统已引起越来越多的关注。在这篇综述中,我们描述了每个必需的QC测试和常规测试方法,然后讨论了直接小型化测试的努力或文献中可以用于小型化QC测试的示例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号